George Medicines Appoints Mark Mallon as Chief Govt Officer and Board Director
London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical firm addressing important unmet want within the therapy of cardiometabolic illness, broadcasts the appointment of Mark Mallon as its new Chief Govt Officer and Board Director, efficient instantly.
Mark brings an in depth observe report of efficiently main the event and commercialization of vital, progressive medicines throughout a number of therapeutic areas together with cardiovascular and metabolic illnesses. Throughout his 24-year profession at AstraZeneca, he held a number of senior management roles together with Govt Vice President of Worldwide and Govt Vice President of Product and Portfolio Technique. Extra just lately, as CEO and Board Director of Ironwood Prescribed drugs, Mark led the profitable transformation of a largely major care enterprise in direction of an organization targeted on making a distinction for sufferers with critical and uncommon gastrointestinal illnesses, with appreciable development and revenue technology.
Mr Mark Mallon, Chief Govt Officer of George Medicines, mentioned: “I’m honored to hitch George Medicines and strongly consider in its mission to increase and enhance the lives of hundreds of thousands of individuals affected by the world’s main causes of loss of life and incapacity, similar to hypertension, diabetes and different widespread cardiometabolic issues.
“The Firm’s lead drug candidate, GMRx2, offers a big, near-term alternative to vary the therapy paradigm for folks dwelling with uncontrolled hypertension – a situation that has seen restricted innovation in latest many years and continues to current a big burden globally, together with in international locations with superior well being methods. Around the globe, solely roughly 1 in 5 adults (21%) with hypertension have it beneath management and, even within the US, just one in 4 adults are reaching their goal blood strain, risking greater charges of morbidity and mortality. I sit up for working with the staff to advance GMRx2 by way of its closing levels of growth and to safe partnering alternatives that may carry the worth of this vital medication to sufferers.”
Professor Anushka Patel, Chair of George Medicines, mentioned: “I’m delighted to announce Mark’s appointment, at a pivotal time for the Firm and its lead part III product candidate, GMRx2, forward of an anticipated US regulatory submitting later this 12 months. I’m assured that his intensive expertise and dedication to bringing progressive, accessible therapies to underserved sufferers worldwide, together with in low- and middle-income international locations, will carry monumental worth to George Medicines. On behalf of the Board, I welcome Mark to the Firm and sit up for working collectively.”
Ends
About George Medicines
George Medicines is a late-stage biopharmaceutical firm addressing important unmet want within the therapy of cardiometabolic illnesses with progressive, mixtures of best-in-class current therapies, designed for optimum efficacy and security.
Combining best-in-class molecules from current medicines in novel low-dose formulations, George Medicines is creating progressive and proprietary therapies to be extra efficacious, safer and accessible than at the moment accessible therapy choices. These multi-mechanism, single-pill mixtures provide the potential to carry important enhancements in scientific outcomes and remedy adherence in sufferers with cardiometabolic issues, together with hypertension and diabetes, every of which stay the main causes of untimely loss of life and incapacity worldwide.
The Firm is constructing a robust and diversified pipeline of patented therapies. GMRx2 is in Section III growth for the therapy of hypertension, together with first line remedy, and for the prevention of recurrent intracerebral haemorrhage (essentially the most extreme kind of stroke); GMRx4 is in Section II growth for the therapy of kind 2 diabetes. Additional analysis applications are underway in coronary heart failure, coronary coronary heart illness and power kidney illness.
George Medicines is a spin-out firm from The George Institute for World Well being, one of many world’s main medical analysis institutes with a give attention to addressing world well being inequity. The Firm is backed by George Well being, the business arm of The George Institute, and Brandon Capital, Australia’s main life sciences enterprise capital agency. For extra data, please go to www.george-medicines.com.
Media contacts
ICR Consilium
David Daley, Lindsey Neville, Isabelle Abdou
[email protected]
Tel: +44 (0) 203 709 5700
